Kimia Therapeutics

Homepage: kimiatx.com

Alternate names: Kimia, Kimia Therapeutics, Inc.

ROR: 05vrwzn56

OpenAlex ID: I4405263369

Permeability Benchmarking: Guidelines for Comparing in Silico, in Vitro, and in Vivo Measurements

2025 · Christian Jorgensen, Raleigh M. Linville, et al. · Journal of Chemical Information and Modeling · 24

Efficacy and safety of CT ‐868, a novel, fully biased, dual glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double‐blind, randomized placebo controlled phase 2 trial

2025 · Manu V. Chakravarthy, Michael A. Elliott, et al. · Diabetes Obesity and Metabolism · 10

D2ML: Models for Direct-to-Biology Small Molecule Screening

2026 · Nigam, AkshatKumar, Amara, Neri, et al. · arXiv (Cornell University)

Abstract 2422: Next-generation chemical biology: Mapping the Purinome druggable space reveals genotype-specific vulnerabilities via phenotypic screening

2026 · Ali Khateb, Ritika Gangaraju, et al. · Cancer Research

Works count: 4

Citation count: 34